Drugs Made In America Acquisition DMII
NASDAQ DMII
$10.14 +0.00 (+0.00%)
As of: Aug 21, 2026 · 2:38 PM EDT

Drugs Made In America Acquisition (DMII) Income from Continuing Operations (2025)

Drugs Made In America Acquisition (DMII) posted quarterly Income from Continuing Operations of 4588973.0 for Q4 2025, up 10041.88% quarter-over-quarter from 46158.0 in Q3 2025.

Drugs Made In America Acquisition (DMII) Income from Continuing Operations (2025) Analysis & Trends

Drugs Made In America Acquisition (DMII) has reported Income from Continuing Operations for 1 consecutive years, with 4588973.0 the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - 2.11 Mn
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - 1.95 Mn
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - 4.40 Mn
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - 3.92 Mn
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - 290,121.00
6 Aldel Financial 397.49 Mn 397.49 Mn - 2.11 Mn
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - 2.65 Mn
8 Gores Holdings X 385.06 Mn 384.87 Mn - 1.88 Mn
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - -
10 CSLM Digital Asset Acquisition Corp III 322.52 Mn 314.90 Mn - -623,674.00

Historic Data

Download Data
DateValue
Dec 31, 2025 4.59 Mn
Sep 30, 2025 -46,158.00